Ceftazidime Dosing: 2g vs 1g for Serious Gram-Negative Infections
For serious gram-negative infections in adults, ceftazidime should be administered at 2g every 8 hours, not 1g. The higher dose is specifically recommended for severe infections, particularly those involving Pseudomonas aeruginosa, multidrug-resistant organisms, or critically ill patients.
Dosing Algorithm by Clinical Scenario
Use 2g every 8 hours for:
- Complicated intra-abdominal infections 1
- Hospital-acquired or ventilator-associated pneumonia 2
- Meningitis 3
- Bone and joint infections 3
- Serious gynecologic infections 3
- Life-threatening infections in immunocompromised patients 3
- Pseudomonas aeruginosa infections (especially in cystic fibrosis patients or ICU settings) 4, 5
- Carbapenem-resistant Pseudomonas aeruginosa (CRPA) when susceptible 4
- Gram-negative endocarditis 6
Use 1g every 8-12 hours for:
- Uncomplicated pneumonia 3
- Mild skin and soft tissue infections 3
- Complicated urinary tract infections (500mg-1g) 3
Key Evidence Supporting Higher Dosing
The FDA label explicitly states that 2g every 8 hours is the standard dose for serious infections 3. Peak serum concentrations with 2g dosing reach 170 mcg/mL compared to only 90 mcg/mL with 1g, providing substantially higher tissue penetration 3.
For Pseudomonas infections specifically, the evidence is particularly compelling. A study of ICU patients with Pseudomonas infections demonstrated that 2g three times daily achieved mean peak concentrations of 58.5 mcg/mL with sustained levels around 5 mcg/mL at 8 hours—critical for time-dependent killing against organisms with higher MICs 5.
The 2022 multidrug-resistant organism guidelines recommend ceftazidime 2g every 8 hours for carbapenem-resistant Pseudomonas when the organism remains susceptible 4. This dosing is essential because inadequate initial therapy for serious gram-negative infections significantly increases mortality 2.
Critical Considerations
For ICU patients with preserved renal function: Even 2g every 8 hours may be insufficient due to augmented renal clearance and increased volume of distribution. French critical care guidelines suggest that doses up to 6-12g daily may be required in patients with augmented renal clearance, and prolonged or continuous infusions should be considered 7.
Timing matters: The 2005 HAP/VAP guidelines emphasize that delayed appropriate therapy increases mortality 2. Starting with inadequate dosing (1g) and escalating later does not reverse the mortality risk associated with initial undertreatment.
Renal adjustment: The 2g dose assumes normal renal function. With creatinine clearance 31-50 mL/min, reduce to 1g every 12 hours; with CrCl 16-30 mL/min, use 1g every 24 hours 3.
Common Pitfall to Avoid
Do not use 1g dosing for serious infections simply because it appears in dosing tables. The FDA label clearly differentiates: 1g is for "usual recommended dosage" in less severe infections, while 2g is explicitly designated for serious infections including those listed above 3. A comparative study showed that while 2g twice daily was equivalent to 1g three times daily for skin infections, this equivalence does not extend to life-threatening or deep-seated infections 8.
Bottom line: In serious gram-negative infections—particularly those involving Pseudomonas, resistant organisms, or critically ill patients—2g every 8 hours is the evidence-based standard dose, providing the pharmacokinetic exposure necessary for optimal clinical and microbiological outcomes.